Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Grilinctus is a multi-ingredient cough syrup developed and manufactured by Franco-Indian Pharmaceuticals. It is formulated for the symptomatic relief of cough and upper respiratory tract symptoms associated with conditions such as the common cold and bronchitis. The medication contains four active components: dextromethorphan hydrobromide, which acts as a centrally-acting cough suppressant; chlorpheniramine maleate, an antihistamine that alleviates allergic symptoms like sneezing and runny nose; and guaifenesin and ammonium chloride, which serve as expectorants to facilitate the clearance of mucus from the airways. This combination approach addresses both the urge to cough and the underlying congestion.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Grilinctus.